Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Suspended 1Completed 1

Sponsor Class

OTHER 6NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 48Gynecologic 47CNS 7Other solid neoplasm 5Sarcoma 4Tumor-Agnostic 2Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Topotecan × Tumor-Agnostic × Clear all
NCT02354547 2026-05-08

A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors

SynerGene Therapeutics, Inc.

Phase 1 Suspended
18 enrolled
Tumor-Agnostic

Neoplasms

NCT00422682 2016-06-10

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

Sanofi

Phase 1 Completed
136 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡